Currently, the CAP and United Kingdom are in the planning and implementation stages for development of such a comprehensive EQA protocol for Ki-67 [2], which will potentially have a major impact on achieving more widespread use of Ki-67 in the clinical management of breast cancer patients. This evidence concerns the gene MKI67 and breast carcinoma.